Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 67
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Chem Biol Interact ; 238: 161-9, 2015 Aug 05.
Artículo en Inglés | MEDLINE | ID: mdl-26145887

RESUMEN

Serum-derived human butyrylcholinesterase (Hu BChE) is a stoichiometric bioscavenger that is being developed as a potential prophylactic nerve agent countermeasure. Previously, we reported the prophylactic efficacy of Hu BChE in Göttingen minipigs against a whole-body exposure to 4.1mg/m(3) of sarin (GB) vapor, which produced lethality over 60min. Since the toxicity of nerve agent is concentration-dependent, in the present study, we investigated the toxic effects of an almost 3-fold higher rate of GB vapor exposure and the ability of Hu BChE to protect minipigs against this exposure. Male minipigs were subjected to: (1) air exposure; (2) GB vapor exposure; or (3) pretreatment with 7.5mg/kg of Hu BChE by i.m. injection, 24h prior to whole-body exposure to 11.4mg/m(3) of GB vapor for 10min. Electrocardiogram, electroencephalogram, and pupil size were monitored throughout exposure. Blood drawn before and throughout exposure was analyzed for blood gases, electrolytes, metabolites, acetylcholinesterase and BChE activities, and amount of GB bound to red blood cells and plasma. A novel finding was that saline-treated animals exposed to GB vapor did not develop any seizures, but manifested a variety of cardiac and whole blood toxic signs and rapidly died due to respiratory failure. Strikingly, pre-treatment with 7.5mg/kg of Hu BChE not only prevented lethality, but also avoided all cardiac toxic signs manifested in the non-treated cohort. Thus, Hu BChE alone can serve as an effective prophylactic countermeasure versus a lethal high-dose exposure to GB vapor.


Asunto(s)
Butirilcolinesterasa/farmacología , Sustancias para la Guerra Química/toxicidad , Sarín/toxicidad , Convulsiones/inducido químicamente , Acetilcolinesterasa/metabolismo , Animales , Análisis Químico de la Sangre , Butirilcolinesterasa/metabolismo , Electrocardiografía , Electroencefalografía , Gases/química , Humanos , Masculino , Miosis/inducido químicamente , Miosis/patología , Insuficiencia Respiratoria/inducido químicamente , Insuficiencia Respiratoria/patología , Convulsiones/patología , Porcinos , Porcinos Enanos
2.
Bioorg Med Chem Lett ; 23(5): 1544-7, 2013 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-23395652

RESUMEN

Chemical warfare nerve agents such as soman exert their toxic effects through an irreversible inhibition of acetylcholinesterase (AChE) and subsequently glutamatergic function, leading to uncontrolled seizures. The natural alkaloid (-)-huperzine A is a potent inhibitor of AChE and has been demonstrated to exert neuroprotection at an appropriate dose. It is hypothesized that analogs of both (+)- and (-)-huperzine A with an improved ability to interact with NMDA receptors together with reduced AChE inhibition will exhibit more effective neuroprotection against nerve agents. In this manuscript, the tested huperzine A analogs 2 and 3 were demonstrated to improve survival of guinea pigs exposed to soman at either 1.2 or 2×LD(50).


Asunto(s)
Alcaloides/química , Alcaloides/farmacología , Inhibidores de la Colinesterasa/química , Fármacos Neuroprotectores/química , Sesquiterpenos/química , Sesquiterpenos/farmacología , Animales , Inhibidores de la Colinesterasa/farmacología , Cobayas , Fármacos Neuroprotectores/farmacología , Soman/toxicidad , Análisis de Supervivencia
3.
Chem Biol Interact ; 203(1): 24-9, 2013 Mar 25.
Artículo en Inglés | MEDLINE | ID: mdl-23044488

RESUMEN

Human serum butyrylcholinesterase (HuBChE) is currently the most suitable bioscavenger for the prophylaxis of highly toxic organophosphate (OP) nerve agents. A dose of 200mg of HuBChE is envisioned as a prophylactic treatment that can protect humans from an exposure of up to 2 × LD50 of soman. The limited availability and administration of multiple doses of this stoichiometric bioscavenger make this pretreatment difficult. Thus, the goal of this study was to produce a smaller enzymatically active HuBChE polypeptide (HBP) that could bind to nerve agents with high affinity thereby reducing the dose of enzyme. Studies have indicated that the three-dimensional structure and the domains of HuBChE (acyl pocket, lip of the active center gorge, and the anionic substrate-binding domain) that are critical for the binding of substrate are also essential for the selectivity and binding of inhibitors including OPs. Therefore, we designed three HBPs by deleting some N- and C-terminal residues of HuBChE by maintaining the folds of the active site core that includes the three active site residues (S198, E325, and H438). HBP-4 that lacks 45 residues from C-terminus but known to have BChE activity was used as a control. The cDNAs for the HBPs containing signal sequences were synthesized, cloned into different mammalian expression vectors, and recombinant polypeptides were transiently expressed in different cell lines. No BChE activity was detected in the culture media of cells transfected with any of the newly designed HBPs, and the inactive polypeptides remained inside the cells. Only enzymatically active HBP-4 was secreted into the culture medium. These results suggest that residues at the N- and C-termini are required for the folding and/or maintenance of HBP into an active stable, conformation.


Asunto(s)
Butirilcolinesterasa/química , Aminoácidos/química , Butirilcolinesterasa/genética , Butirilcolinesterasa/metabolismo , Butirilcolinesterasa/farmacología , Dominio Catalítico , Cristalografía por Rayos X , Células HEK293 , Humanos , Modelos Moleculares , Simulación de Dinámica Molecular , Compuestos Organofosforados/antagonistas & inhibidores , Compuestos Organofosforados/toxicidad , Fragmentos de Péptidos/química , Fragmentos de Péptidos/genética , Fragmentos de Péptidos/farmacología , Pliegue de Proteína , Estructura Terciaria de Proteína , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/farmacología , Eliminación de Secuencia , Soman/antagonistas & inhibidores , Soman/toxicidad
4.
Chem Biol Interact ; 203(1): 120-4, 2013 Mar 25.
Artículo en Inglés | MEDLINE | ID: mdl-23123250

RESUMEN

The neuropathologic mechanisms after exposure to lethal doses of nerve agent are complex and involve multiple biochemical pathways. Effective treatment requires drugs that can simultaneously protect by reversible binding to the acetylcholinesterase (AChE) and blocking cascades of seizure related brain damage, inflammation, neuronal degeneration as well as promoting induction of neuroregeneration. [-]-Huperzine A ([-]-Hup A), is a naturally occurring potent reversible AChE inhibitor that penetrates the blood-brain barrier. It also has several neuroprotective effects including modification of beta-amyloid peptide, reduction of oxidative stress, anti-inflammatory, anti-apoptotic and induction and regulation of nerve growth factor. Toxicities at higher doses restrict the neuroporotective ability of [-]-Hup A for treatment. The synthetic stereoisomer, [+]-Hup A, is less toxic due to poor AChE inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity. [+]-Hup A block the N-methyl-D-aspartate (NMDA)-induced seizure in rats, reduce excitatory amino acid induced neurotoxicity and also prevent soman induced toxicity with minimum performance decrement. Unique combinations of two stereo-isomers of Hup A may provide an excellent pre/post-treatment drug for the nerve agent induced seizure/status epilepticus. We investigated a combination of [+]-Hup A with a small dose of [-]-Hup A ([+] and [-]-Hup A) against soman toxicity. Our data showed that pretreatment with a combination [+] and [-]-Hup A significantly increased the survival rate and reduced behavioral abnormalities after exposure to 1.2 × LD(50) soman compared to [+]-Hup A in guinea pigs. In addition, [+] and [-]-Hup A pretreatment inhibited the development of high power of EEG better than [+]-Hup A pretreatment alone. These data suggest that a combination of [+] and [-]-Hup A offers better protection than [+]-Hup A and serves as a potent medical countermeasure against lethal dose nerve agent toxicity in guinea pigs.


Asunto(s)
Alcaloides/administración & dosificación , Inhibidores de la Colinesterasa/administración & dosificación , Fármacos Neuroprotectores/administración & dosificación , Sesquiterpenos/administración & dosificación , Soman/antagonistas & inhibidores , Soman/toxicidad , Acetilcolinesterasa/metabolismo , Alcaloides/química , Animales , Encéfalo/efectos de los fármacos , Encéfalo/enzimología , Sustancias para la Guerra Química/toxicidad , Inhibidores de la Colinesterasa/química , Cobayas , Masculino , Fármacos Neuroprotectores/química , Ratas , Convulsiones/inducido químicamente , Convulsiones/prevención & control , Sesquiterpenos/química , Estereoisomerismo
5.
Chem Biol Interact ; 203(1): 172-6, 2013 Mar 25.
Artículo en Inglés | MEDLINE | ID: mdl-23220586

RESUMEN

Exogenously administered human serum butyrylcholinesterase (Hu BChE) was demonstrated to function as a bioscavenger of highly toxic organophosphorus (OP) compounds in several animal species. Since the enzyme is isolated from human serum, it is currently the most suitable pretreatment for human use. A dose of 200-300 mg/70 kg human adult is projected to provide protection from 2 X LD(50) of soman. Due to the limited supply of Hu BChE, strategies aimed at reducing the dose of enzyme are being explored. In this study, we investigated the effect of modification with polyethylene glycol (PEG) on the in vivo stability of Hu BChE. Mice were given two injections of either Hu BChE or Hu BChE modified with PEG-5K or PEG-20K, six weeks apart. Pharmacokinetic parameters, such as mean residence time (MRT), maximal concentration (C(max)), elimination half-life (T(1/2)), and area under the plasma concentration time curve extrapolated to infinity (AUC), were determined. For the first injection, values for MRT, T(1/2), Cmax, and AUC for PEG-5K-Hu BChE and PEG-20K-Hu BChE were similar to those for Hu BChE. These values for the second injection of Hu BChE as well as PEG-Hu BChEs were lower as compared to those for the first injections, likely due to antibody-mediated clearance.


Asunto(s)
Butirilcolinesterasa/sangre , Adulto , Animales , Antídotos/administración & dosificación , Antídotos/química , Antídotos/farmacocinética , Butirilcolinesterasa/administración & dosificación , Butirilcolinesterasa/química , Sustancias para la Guerra Química/toxicidad , Inhibidores de la Colinesterasa/toxicidad , Estabilidad de Enzimas , Humanos , Masculino , Ratones , Ratones Endogámicos BALB C , Polietilenglicoles/química , Soman/toxicidad
6.
Inhal Toxicol ; 24(9): 539-49, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22860999

RESUMEN

We evaluated the efficacy of aerosolized acetylcholinesterase (AChE) reactivator oxime MMB-4 in combination with the anticholinergic atropine sulfate for protection against respiratory toxicity and lung injury following microinstillation inhalation exposure to nerve agent soman (GD) in guinea pigs. Anesthetized animals were exposed to GD (841 mg/m(3), 1.2 LCt(50)) and treated with endotracheally aerosolized MMB-4 (50 µmol/kg) plus atropine sulfate (0.25 mg/kg) at 30 sec post-exposure. Treatment with MMB-4 plus atropine increased survival to 100% compared to 38% in animals exposed to GD. Decreases in the pulse rate and blood O(2) saturation following exposure to GD returned to normal levels in the treatment group. The body-weight loss and lung edema was significantly reduced in the treatment group. Similarly, bronchoalveolar cell death was significantly reduced in the treatment group while GD-induced increase in total cell count was decreased consistently but was not significant. GD-induced increase in bronchoalveolar protein was diminished after treatment with MMB-4 plus atropine. Bronchoalveolar lavage AChE and BChE activity were significantly increased in animals treated with MMB-4 plus atropine at 24 h. Lung and diaphragm tissue also showed a significant increase in AChE activity in the treatment group. Treatment with MMB-4 plus atropine sulfate normalized various respiratory dynamics parameters including respiratory frequency, tidal volume, peak inspiratory and expiratory flow, time of inspiration and expiration, enhanced pause and pause post-exposure to GD. Collectively, these results suggest that aerosolization of MMB-4 plus atropine increased survival, decreased respiratory toxicity and lung injury following GD inhalation exposure.


Asunto(s)
Atropina/administración & dosificación , Inhibidores de la Colinesterasa/toxicidad , Reactivadores de la Colinesterasa/administración & dosificación , Oximas/administración & dosificación , Sustancias Protectoras/administración & dosificación , Soman/toxicidad , Acetilcolinesterasa/metabolismo , Administración por Inhalación , Aerosoles , Animales , Líquido del Lavado Bronquioalveolar/química , Líquido del Lavado Bronquioalveolar/citología , Butirilcolinesterasa/metabolismo , Sustancias para la Guerra Química/toxicidad , Combinación de Medicamentos , Cobayas , Pulmón/efectos de los fármacos , Pulmón/enzimología , Pulmón/patología , Pulmón/fisiopatología , Masculino
7.
Neurotoxicol Teratol ; 34(3): 323-30, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22402122

RESUMEN

The effects of a large dose of human serum butyrylcholinesterase (HuBChE) were evaluated in rhesus monkeys using a serial-probe recognition (SPR) task designed to assess attention and short-term memory. Each monkey received an intravenous injection of 150 mg (105,000 U or 30 mg/kg) of HuBChE 60 min prior to testing on the SPR task. Concurrent with the cognitive-behavioral assessment, blood was collected at various time points throughout the study and was analyzed for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities, anti-BChE antibody production and gross clinical pathology (i.e., complete blood count and clinical chemistry panel). HuBChE revealed a peak blood activity of 227 U/ml at 5 min after intravenous injection and a mean residence time of approximately 72 h. No cognitive-behavioral decrements of any kind in SPR performance and no toxic signs in clinical pathology were detected in any of the blood assays during the 5 weeks of observation. Anti-HuBChE antibodies peaked at about 14 days after injection, with no concomitant behavioral changes. These results demonstrate the behavioral and physiological safety of HuBChE in rhesus monkeys and support its development as a bioscavenger for the prophylaxis of chemical warfare agent toxicity in humans.


Asunto(s)
Conducta Animal , Butirilcolinesterasa/sangre , Animales , Antídotos/efectos adversos , Conducta Animal/efectos de los fármacos , Conducta Animal/fisiología , Recuento de Células Sanguíneas , Butirilcolinesterasa/efectos adversos , Butirilcolinesterasa/inmunología , Femenino , Humanos , Inmunoglobulina G/sangre , Inyecciones Intravenosas , Pruebas de Función Renal , Pruebas de Función Hepática , Macaca mulatta
8.
Toxicol Lett ; 210(1): 87-94, 2012 Apr 05.
Artículo en Inglés | MEDLINE | ID: mdl-22301377

RESUMEN

Human paraoxonase 1 (PON1), a 45kDa arylesterase associated with circulating high density lipoproteins (HDL), has been described as an anti-atherogenic element in cardiovascular disorders. The efficacy of PON1 as a catalytic bioscavenger against OP and CWNA toxicity has been on debate for the last few decades. Hydrolysis of various organophosphates (OPs) and chemical warfare nerve agents (CWNAs) by PON1 has been demonstrated in both in vitro and in vivo experiments. Recently, we established the protective efficacy of human and rabbit serum purified PON1 as well as human recombinant PON1 expressed in Trichoplusia ni larvae against nerve agent toxicity in guinea pigs. Exogenous administration of purified PON1 was effective in protecting against 1.2 X LCt(50) of sarin and soman administered endotracheally with microinstillation technology. However, the short half-life of exogenously administered PON1, probably due to poor association with circulating HDL, warrant alternative approaches for successful utility of PON1 in the treatment of OP/CWNA toxicity. In this mini review, we address the pros and cons of current PON1 prophylaxis and propose potential solutions for successful development of PON1 as an effective catalytic bioscavenger.


Asunto(s)
Arildialquilfosfatasa/uso terapéutico , Sustancias para la Guerra Química/metabolismo , Organofosfatos/antagonistas & inhibidores , Animales , Arildialquilfosfatasa/farmacocinética , Cobayas , Semivida , Humanos , Organofosfatos/metabolismo , Conejos
9.
Neurotoxicology ; 33(2): 169-77, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22245390

RESUMEN

The chemical warfare nerve agent, soman irreversibly inhibits acetylcholinesterase (AChE) leading to hypercholinergy and seizures which trigger glutamate toxicity and status epilepticus ultimately resulting in neuropathology and neurobehavioral deficits. The standard emergency treatment comprising of anticholinergic, AChE reactivator and anticonvulsant does not completely protect against soman toxicity. We have evaluated imidazenil, a new anticonvulsant imidazo benzodiazepine with high affinity and intrinsic efficacy at α5-, α2-, and α3- but low intrinsic efficacy at α1-containing GABA(A) receptors and is devoid of cardiorespiratory depression, sedative/hypnoitc and amnestic actions and does not elicit tolerance and dependence liabilities unlike diazepam, for protection against soman toxicity. Guinea pigs implanted with bipotential radiotelemetry probes for recording EEG and ECG were administered with 26 µg/kg pyridostigmine bromide 30 min prior to 2× LD(50) soman exposure and 1 min later treated with a combination of 2mg/kg atropine sulfate and 25mg/kg 2-pralidoxime and various doses of imidazenil. Intramuscular administration of imidazenil, dose-dependently protected against 2× LD(50) of soman toxicity up to 1mg/kg. Further increase in the dose of imidazenil to 2.5mg/kg was less effective than 1mg/kg probably due to non-specific actions at sites other than GABA(A) receptors. Compared to vehicle group, 1mg/kg imidazenil treatment showed optimal increase in survival rate, reduction in behavioral manifestations and high power of EEG spectrum as well as neuronal necrosis. These data suggest that imidazenil is an effective anticonvulsant for medical countermeasure against soman-induced toxicity.


Asunto(s)
Benzodiazepinas/uso terapéutico , Sustancias para la Guerra Química/toxicidad , Imidazoles/uso terapéutico , Fármacos Neuroprotectores/uso terapéutico , Síndromes de Neurotoxicidad/tratamiento farmacológico , Síndromes de Neurotoxicidad/etiología , Soman/toxicidad , Acetilcolinesterasa/sangre , Acetilcolinesterasa/metabolismo , Análisis de Varianza , Animales , Atropina/uso terapéutico , Peso Corporal/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/enzimología , Reactivadores de la Colinesterasa/uso terapéutico , Modelos Animales de Enfermedad , Esquema de Medicación , Electrocardiografía/métodos , Electroencefalografía/métodos , Cobayas , Dosificación Letal Mediana , Masculino , Antagonistas Muscarínicos/uso terapéutico , Compuestos de Pralidoxima/uso terapéutico , Convulsiones/inducido químicamente , Convulsiones/prevención & control , Telemetría , Factores de Tiempo
10.
J Control Release ; 160(2): 217-24, 2012 Jun 10.
Artículo en Inglés | MEDLINE | ID: mdl-22079949

RESUMEN

We formulated a new gene delivery system based on targeted liposomes. The efficacy of the delivery system was demonstrated in in vitro and in vivo models. The targeting moiety consists of a high-affinity 7-amino-acid peptide, covalently and evenly conjugated to the liposome surface. The targeting peptide acts as an endothelin antagonist, and accelerates liposome binding and internalization. It is devoid of other biological activity. Liposomes with high phosphatidyl serine (PS) were specially formulated to help their fusion with the endosomal membrane at low pH and enable release of the liposome payload into the cytoplasm. A DNA payload, pre-compressed by protamine, was encapsulated into the liposomes, which directed the plasmid into the cell's nucleus. Upon exposure to epithelial cells, binding of the liposomes occurred within 5-10 min, followed by facilitated internalization of the complex. Endosomal escape was complete within 30 min, followed by DNA accumulation in the nucleus 2h post-transfection. A549 lung epithelial cells transfected with plasmid encoding for GFP encapsulated in targeted liposomes expressed significantly more protein than those transfected with plasmid complexed with Lipofectamine. The intra-tracheal instillation of plasmid encoding for GFP encapsulated in targeted liposomes into rat lungs resulted in the expression of GFP in bronchioles and alveoli within 5 days. These results suggest that this delivery system has great potential in targeting genes to lungs.


Asunto(s)
Portadores de Fármacos/química , Endotelinas/antagonistas & inhibidores , Células Epiteliales/metabolismo , Técnicas de Transferencia de Gen , Pulmón/metabolismo , Animales , Transporte Biológico , Bronquios/metabolismo , Bronquios/patología , Línea Celular Tumoral , Núcleo Celular/efectos de los fármacos , Núcleo Celular/metabolismo , Citoplasma/efectos de los fármacos , Citoplasma/metabolismo , ADN/administración & dosificación , ADN/genética , Portadores de Fármacos/farmacología , Endocitosis/efectos de los fármacos , Células Epiteliales/patología , Proteínas Fluorescentes Verdes/genética , Humanos , Instilación de Medicamentos , Lípidos/química , Lípidos/farmacología , Liposomas , Pulmón/patología , Oligopéptidos/química , Oligopéptidos/farmacología , Fosfatidilserinas/química , Fosfatidilserinas/farmacología , Plásmidos , Unión Proteica , Ratas , Tráquea/metabolismo , Tráquea/patología , Transfección
11.
Toxicol In Vitro ; 26(1): 182-8, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22120822

RESUMEN

Human prolidase (PROL), which has structural homology to bacterial organophosphate acid anhydrolase that hydrolyze organophosphates and nerve agents has been proposed recently as a potential catalytic bioscavenger. To develop PROL as a catalytic bioscavenger, we evaluated the in vitro hydrolysis efficiency of purified recombinant human PROL against organophosphates and nerve agents. Human liver PROL was purified by chromatographic procedures, whereas recombinant human skin and kidney PROL was expressed in Trichoplusia ni larvae, affinity purified and analyzed by gel electrophoresis. The catalytic efficiency of PROL against diisopropylfluorophosphate (DFP) and nerve agents was evaluated by acetylcholinesterase back-titration assay. Partially purified human liver PROL hydrolyzed DFP and various nerve agents, which was abolished by specific PROL inhibitor showing the specificity of hydrolysis. Both the recombinant human skin and kidney PROL expressed in T. ni larvae showed ∼99% purity and efficiently hydrolyzed DFP and sarin. In contrast to human liver PROL, both skin and kidney PROL showed significantly low hydrolyzing potential against nerve agents soman, tabun and VX. In conclusion, compared to human liver PROL, recombinant human skin and kidney PROL hydrolyze only DFP and sarin showing the substrate specificity of PROL from various tissue sources.


Asunto(s)
Sustancias para la Guerra Química/química , Inhibidores de la Colinesterasa/química , Dipeptidasas/química , Proteínas Recombinantes/química , Acetilcolinesterasa/química , Humanos , Hidrólisis , Isoflurofato/química , Riñón/enzimología , Hígado/enzimología , Organofosfatos/química , Compuestos Organotiofosforados/química , Sarín/química , Piel/enzimología
12.
Toxicol Mech Methods ; 22(4): 250-9, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22145985

RESUMEN

Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities were measured in the blood and tissues of animals that are treated with a number of endotracheally aerosolized therapeutics for protection against inhalation toxicity to sarin. Therapeutics included, aerosolized atropine methyl bromide (AMB), scopolamine or combination of AMB with salbutamol, sphingosine 1-phosphate, keratinocyte growth factor, adenosine A1 receptor antisense oligonucleotide (EPI2010), 2,3-diacetyloxybenzoic acid (2,3 DABA), oxycyte, and survanta. Guinea pigs exposed to 677.4 mg/m(3) or 846.5 mg/m(3) (1.2 LCt(50)) sarin for 4 min using a microinstillation inhalation exposure technique and treated 1 min later with the aerosolized therapeutics. Treatment with all therapeutics significantly increased the survival rate with no convulsions throughout the 24 h study period. Blood AChE activity determined using acetylthiocholine as substrate showed 20% activity remaining in sarin-exposed animals compare to controls. In aerosolized AMB and scopolamine-treated animals the remaining AChE activity was significantly higher (45-60%) compared to sarin-exposed animals (p < 0.05). Similarly, treatment with all the combination therapeutics resulted in significant increase in blood AChE activity in comparison to sarin-exposed animals although the increases varied between treatments (p < 0.05). BChE activity was increased after treatment with aerosolized therapeutics but was lesser in magnitude compared to AChE activity changes. Various tissues showed elevated AChE activity after therapeutic treatment of sarin-exposed animals. Increased AChE and BChE activities in animals treated with nasal therapeutics suggest that enhanced breathing and reduced respiratory toxicity/lung injury possibly contribute to rapid normalization of chemical warfare nerve agent inhibited cholinesterases.


Asunto(s)
Acetilcolinesterasa/metabolismo , Broncodilatadores/uso terapéutico , Inhibidores de la Colinesterasa/toxicidad , Antagonistas Muscarínicos/uso terapéutico , Sarín/toxicidad , Acetilcolinesterasa/sangre , Animales , Antídotos/uso terapéutico , Butirilcolinesterasa/sangre , Butirilcolinesterasa/metabolismo , Sustancias para la Guerra Química/toxicidad , Cobayas , Pulmón/efectos de los fármacos , Enfermedades Pulmonares/inducido químicamente , Enfermedades Pulmonares/enzimología , Masculino , Terapia Respiratoria
13.
Biochem Pharmacol ; 82(12): 1984-93, 2011 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-21968035

RESUMEN

Human serum butyrylcholinesterase (Hu BChE) is a stoichiometric bioscavenger that is being developed as a prophylactic countermeasure against organophosphorus nerve agents. This study was designed to evaluate the efficacy of Hu BChE against whole-body inhalation exposure to a lethal dose of sarin (GB) vapor. Male Göttingen minipigs were subjected to: air exposure, GB vapor exposure, or pretreatment with Hu BChE followed by GB vapor exposure. Hu BChE was administered by i.m. injection 24 h prior to exposure to 4.1 mg/m(3) of GB vapor for 60 min. Electrocardiograms (ECG), electroencephalograms (EEG), and pupil size were recorded throughout exposure. Blood drawn before and throughout exposure was analyzed for blood gases, electrolytes, metabolites, acetylcholinesterase and BChE activities, and amount of GB present. Untreated animals exposed to GB vapor exhibited cardiac abnormalities and generalized seizures, ultimately succumbing to respiratory failure. Pretreatment with 3.0 or 6.5 mg/kg of Hu BChE delayed blood gas and acid-base disturbances and the onset of cardiac and neural toxic signs, but failed to increase survivability. Pretreatment with 7.5 mg/kg of Hu BChE, however, completely prevented toxic signs, with blood chemistry and ECG and EEG parameters indistinguishable from control during and after GB exposure. GB bound in plasma was 200-fold higher than plasma from pigs that did not receive Hu BChE, suggesting that Hu BChE scavenged GB in blood and prevented it from reaching other tissues. Thus, prophylaxis with Hu BChE alone not only increased survivability, but also prevented cardiac abnormalities and neural toxicity in minipigs exposed to a lethal dose of GB vapor.


Asunto(s)
Arritmias Cardíacas/prevención & control , Butirilcolinesterasa/administración & dosificación , Sustancias para la Guerra Química/toxicidad , Insuficiencia Respiratoria/prevención & control , Sarín/toxicidad , Convulsiones/prevención & control , Acetilcolinesterasa/sangre , Animales , Arritmias Cardíacas/inducido químicamente , Butirilcolinesterasa/sangre , Relación Dosis-Respuesta a Droga , Humanos , Masculino , Insuficiencia Respiratoria/inducido químicamente , Convulsiones/inducido químicamente , Porcinos , Porcinos Enanos
14.
Int J Toxicol ; 30(6): 639-49, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21960666

RESUMEN

The protective efficacy of the antimuscarinic agent scopolamine was evaluated against soman (o-pinacolyl methylphosphonofluoridate [GD])-induced respiratory toxicity in guinea pigs. Anesthetized animals were exposed to GD (841 mg/m(3)) by microinstillation inhalation exposure and treated 30 seconds later with endotracheally aerosolized scopolamine (0.25 mg/kg) and allowed to recover for 24 hours. Treatment with scopolamine significantly increased survival and reduced clinical signs of toxicity and body weight loss in GD-exposed animals. Analysis of bronchoalveolar lavage (BAL) fluid showed normalization of GD-induced increased cell death, total cell count, and protein following scopolamine treatment. The BAL fluid acetylcholinesterase and butyrylcholinesterase levels were also increased by scopolamine treatment. Respiratory dynamics parameters were normalized at 4 and 24 hours post-GD exposure in scopolamine-treated animals. Lung histology showed that scopolamine treatment reduced bronchial epithelial and subepithelial inflammation and multifocal alveolar septal edema. These results suggest that aerosolized scopolamine considerably protects against GD-induced respiratory toxicity.


Asunto(s)
Sustancias para la Guerra Química/toxicidad , Pulmón/efectos de los fármacos , Antagonistas Muscarínicos/farmacología , Sustancias Protectoras/farmacología , Escopolamina/farmacología , Soman/toxicidad , Acetilcolinesterasa/sangre , Acetilcolinesterasa/metabolismo , Aerosoles , Animales , Líquido del Lavado Bronquioalveolar/química , Líquido del Lavado Bronquioalveolar/citología , Butirilcolinesterasa/sangre , Butirilcolinesterasa/metabolismo , Recuento de Células , Cobayas , Pulmón/metabolismo , Pulmón/patología , Masculino , Pruebas de Función Respiratoria , Tráquea/efectos de los fármacos , Tráquea/patología
15.
Neurochem Res ; 36(12): 2381-90, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21822920

RESUMEN

The chemical warfare nerve agent (CWNA) soman irreversibly inhibits acetylcholinesterase (AChE) causing seizure, neuropathology and neurobehavioral deficits. Pyridostigmine bromide (PB), the currently approved pretreatment for soman, is a reversible AChE inhibitor that does not cross the blood-brain barrier (BBB) to protect against central nervous system damage. [-]-Huperzine A, a natural reversible AChE inhibitor, rapidly passes through the BBB and has numerous neuroprotective properties that are beneficial for protection against soman. However, [-]-Huperzine A is toxic at higher doses due to potent AChE inhibition which limits the utilization of its neuroprotective properties. [+]-Huperzine A, a synthetic stereoisomer of [-]-Huperzine A and a weak inhibitor of AChE, is non-toxic. In this study, we evaluated the efficacy of [+]-Huperzine A for protection against soman toxicity in guinea pigs. Pretreatments with [+]-Huperzine A, i.m., significantly increased the survival rate in a dose-dependent manner against 1.2× LD(50) soman exposures. Behavioral signs of soman toxicity were significantly reduced in 20 and 40 mg/kg [+]-Huperzine A treated animals at 4 and 24 h compared to vehicle and PB controls. Electroencephalogram (EEG) power spectral analysis showed that [+]-Huperzine A significantly reduces soman-induced seizure compared to PB. [+]-Huperzine A (40 mg/kg) preserved higher blood and brain AChE activity compared to PB in soman exposed animals. These data suggest that [+]-Huperzine A protects against soman toxicity stronger than PB and warrant further development as a potent medical countermeasure against CWNA poisoning.


Asunto(s)
Alcaloides/uso terapéutico , Inhibidores de la Colinesterasa/uso terapéutico , Sesquiterpenos/uso terapéutico , Soman/toxicidad , Acetilcolinesterasa/metabolismo , Animales , Barrera Hematoencefálica/metabolismo , Temperatura Corporal/efectos de los fármacos , Sustancias para la Guerra Química/toxicidad , Cobayas , Masculino , Fármacos Neuroprotectores/administración & dosificación , Bromuro de Piridostigmina/metabolismo , Bromuro de Piridostigmina/uso terapéutico , Convulsiones/inducido químicamente , Convulsiones/prevención & control , Estereoisomerismo
16.
Toxicol Mech Methods ; 21(6): 463-72, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21651338

RESUMEN

Sarin is a volatile nerve agent that has been used in the Tokyo subway attack. Inhalation is predicted to be the major route of exposure if sarin is used in war or terrorism. Currently available treatments are limited for effective postexposure protection against sarin under mass casualty scenario. Nasal drug delivery is a potential treatment option for mass casualty under field conditions. We evaluated the efficacy of endotracheal administration of muscarinic antagonist scopolamine, a secretion blocker which effectively crosses the blood-brain barrier for protection against sarin inhalation toxicity. Age and weight matched male Hartley guinea pigs were exposed to 677.4 mg/m³ or 846.5 mg/ m³ (1.2 × LCt50) sarin by microinstillation inhalation exposure for 4 min. One minute later, the animals exposed to 846.5 mg/ m³ sarin were treated with endotracheally aerosolized scopolamine (0.25 mg/kg) and allowed to recover for 24 h for efficacy evaluation. The results showed that treatment with scopolamine increased the survival rate from 20% to 100% observed in untreated sarin-exposed animals. Behavioral symptoms of nerve agent toxicity including, convulsions and muscular tremors were reduced in sarin-exposed animals treated with scopolamine. Sarin-induced body weight loss, decreased blood O2 saturation and pulse rate were returned to basal levels in scopolamine-treated animals. Increased bronchoalveolar lavage (BAL) cell death due to sarin exposure was returned to normal levels after treatment with scopolamine. Taken together, these data indicate that postexposure treatment with aerosolized scopolamine prevents respiratory toxicity and protects against lethal inhalation exposure to sarin in guinea pigs.


Asunto(s)
Antídotos/uso terapéutico , Sustancias para la Guerra Química/toxicidad , Antagonistas Colinérgicos/uso terapéutico , Inhibidores de la Colinesterasa/toxicidad , Exposición por Inhalación/efectos adversos , Sarín/toxicidad , Escopolamina/uso terapéutico , Aerosoles , Animales , Antídotos/administración & dosificación , Conducta Animal/efectos de los fármacos , Antagonistas Colinérgicos/administración & dosificación , Inhibidores de la Colinesterasa/administración & dosificación , Relación Dosis-Respuesta a Droga , Cobayas , Frecuencia Cardíaca/efectos de los fármacos , Masculino , Oxígeno/sangre , Sustancias Protectoras/administración & dosificación , Sustancias Protectoras/uso terapéutico , Mucosa Respiratoria/efectos de los fármacos , Sarín/administración & dosificación , Escopolamina/administración & dosificación , Convulsiones/inducido químicamente , Convulsiones/prevención & control , Análisis de Supervivencia , Temblor/inducido químicamente , Temblor/prevención & control , Pérdida de Peso/efectos de los fármacos
17.
Inhal Toxicol ; 23(4): 182-95, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21456952

RESUMEN

The efficacy of endotracheal aerosolization of atropine sulfate for protection against soman (GD)-induced respiratory toxicity was investigated using microinstillation technique in guinea pigs. GD (841 mg/m(3), 1.3 LCt(50) or 1121 mg/m(3), 1.7 LCt(50)) was aerosolized endotracheally to anesthetized male guinea pigs that were treated with atropine sulfate (5.0 mg/kg) 30 s postexposure by endotracheal microinstillation. Animals exposed to 841 mg/m(3) and 1121 mg/m(3)GD resulted in 31 and 13% while treatment with atropine sulfate resulted in 100 and 50% survival, respectively. Cholinergic symptoms and increased body weight loss were reduced in atropine-treated animals compared to GD controls. Diminished pulse rate and blood O(2) saturation in GD-exposed animals returned to normal levels after atropine treatment. Increased cell death, total cell count and protein in the bronchoalveolar fluid (BALF) in GD-exposed animals returned to normal levels following atropine treatment. GD exposure increased glutathione and superoxide dismutase levels in BALF and that were reduced in animals treated with atropine. Respiratory parameters measured by whole-body barometric plethysmography revealed that treatment with atropine sulfate resulted in normalization of respiratory frequency, tidal volume, time of expiration, time of inspiration, end expiratory pause, pseudo lung resistance (Penh) and pause at 4 and 24 h post 841 mg/m(3) GD exposure. Lung histopathology showed that atropine treatment reduced bronchial epithelial subepithelial inflammation and multifocal alveolar septal edema. These results suggest that endotracheal aerosolization of atropine sulfate protects against respiratory toxicity and lung injury induced by microinstillation inhalation exposure to lethal doses of GD.


Asunto(s)
Atropina/farmacología , Exposición por Inhalación/efectos adversos , Enfermedades Respiratorias/inducido químicamente , Enfermedades Respiratorias/prevención & control , Soman/toxicidad , Tráquea/metabolismo , Acetilcolinesterasa/sangre , Acetilcolinesterasa/metabolismo , Administración por Inhalación , Animales , Peso Corporal/efectos de los fármacos , Líquido del Lavado Bronquioalveolar/química , Butirilcolinesterasa/sangre , Butirilcolinesterasa/metabolismo , Sustancias para la Guerra Química/toxicidad , Cobayas , Frecuencia Cardíaca , Dosificación Letal Mediana , Pulmón/efectos de los fármacos , Pulmón/patología , Masculino , Pletismografía Total , Sarín/toxicidad , Volumen de Ventilación Pulmonar/efectos de los fármacos
18.
Int J Toxicol ; 30(3): 348-57, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21527644

RESUMEN

Barometric whole-body plethysmography (WBP) was used to examine pulmonary functions at 4 and 24 hours postexposure to soman (GD) in guinea pigs without therapeutics to improve survival. Endotracheal aerosolization by microinstillation was used to administer GD (280, 561, and 841 mg/m(3)) or saline to anesthetized guinea pigs. Significant increases in respiratory frequency (RF), tidal volume (TV), and minute volume (MV) were observed with 841 mg/m(3) GD at 4 hours and that were reduced at 24 hours postexposure. A dose-dependent increase in peak inspiration flow and peak expiration flow was present at 4-hour post-GD exposure that was reduced at 24 hours. Time of inspiration and expiration were decreased in all doses of GD exposure at 4 and 24 hours, with significant inhibition at 841 mg/m(3). End-expiratory pause (EEP) increased at 280 and 561 mg/m(3), but decreased in animals exposed 841 mg/m(3) at 24 hours postexposure. Pseudo-lung resistance (Penh) and pause followed similar patterns and increased at 4 hours, but decreased at 24 hours postexposure to 841 mg/m(3) of GD compared to control. These studies indicate GD exposure induces dose-dependent changes in pulmonary function that are significant at 841 mg/m(3) at 4 hours and remains 24 hours postexposure. Furthermore, at 4 hours, GD induces bronchoconstriction possibly due to copious airway secretion and ongoing lung injury in addition to cholinergic effects, while at 24 hours GD induces bronchodilation a possible consequence of initial compensatory mechanisms.


Asunto(s)
Sustancias para la Guerra Química/toxicidad , Pulmón/efectos de los fármacos , Pruebas de Función Respiratoria , Soman/toxicidad , Animales , Peso Corporal/efectos de los fármacos , Cobayas , Pulmón/fisiología , Pletismografía
19.
Toxicol In Vitro ; 25(4): 905-13, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21382471

RESUMEN

Paraoxonase 1 (PON1) has been described as a potential catalytic bioscavenger due to its ability to hydrolyze organophosphate (OP) insecticides and nerve agents. In vitro catalytic efficiency of purified human and rabbit serum PON1 against different OP substrates was compared to human recombinant PON1, expressed in Trichoplusia ni larvae. Highly purified human and rabbit serum PON1s were prepared by multiple chromatography methods. Purified enzymes showed higher catalytic activity with the substrate p-nitrophenyl acetate compared to diethyl paraoxon. The hydrolyzing potential of PON1s against multiple OPs was evaluated by using an in vitro acetylcholinesterase back-titration assay. Significant differences in the catalytic efficiency of all the three PON1s with regard to various OP substrates were observed. Purified PON1s showed higher catalytic activity towards diisopropylfluorophosphate followed by diethylparaoxon compared to dimethyl paraoxon. Heat inactivation or incubation of PON1 with specific inhibitor resulted in complete loss of the enzyme catalytic activity indicating that OP hydrolysis was intrinsic to PON1. In conclusion, purified PON1s from multiple sources show significant differences in the catalytic activity against several OP substrates. These results underscore the importance of systematic analysis of candidate PON1 molecules for developing as an effective catalytic bioscavenger against toxic OPs and chemical warfare nerve agents.


Asunto(s)
Arildialquilfosfatasa/farmacología , Sustancias para la Guerra Química/metabolismo , Insecticidas/metabolismo , Compuestos Organofosforados/metabolismo , Acetilcolinesterasa/metabolismo , Animales , Catálisis , Calor , Humanos , Hidrólisis , Larva , Mariposas Nocturnas , Conejos
20.
Toxicol Lett ; 202(3): 203-8, 2011 May 10.
Artículo en Inglés | MEDLINE | ID: mdl-21329748

RESUMEN

To explore the efficacy of paraoxonase 1 (PON1) as a catalytic bioscavenger, we evaluated human recombinant PON1 (rePON1) expressed in Trichoplusia ni larvae against sarin and soman toxicity using microinstillation inhalation exposure in guinea pigs. Animals were pretreated intravenously with catalytically active rePON1, followed by exposure to 1.2 X LCt50 sarin or soman. Administration of 5 units of rePON1 showed mild increase in the blood activity of the enzyme after 30 min, but protected the animals with a significant increase in survival rate along with minimal signs of nerve agent toxicity. Recombinant PON1 pretreated animals exposed to sarin or soman prevented the reduction of blood O2 saturation and pulse rate observed after nerve agent exposure. In addition, rePON1 pretreated animals showed significantly higher blood PON1, acetylcholinesterase (AChE), and butyrylcholinesterase activity after nerve agent exposure compared to the respective controls without treatments. AChE activity in different brain regions of rePON1 pretreated animals exposed to sarin or soman were also significantly higher than respective controls. The remaining activity of blood PON1, cholinesterases and brain AChE in PON1 pretreated animals after nerve agent exposure correlated with the survival rate. In summary, these data suggest that human rePON1 protects against sarin and soman exposure in guinea pigs.


Asunto(s)
Lesión Pulmonar Aguda/prevención & control , Arildialquilfosfatasa/farmacología , Sustancias para la Guerra Química/toxicidad , Fármacos Neuroprotectores/farmacología , Sarín/toxicidad , Soman/toxicidad , Lesión Pulmonar Aguda/sangre , Animales , Encéfalo/efectos de los fármacos , Encéfalo/enzimología , Colinesterasas/sangre , Cobayas , Humanos , Exposición por Inhalación , Inyecciones Intravenosas , Instilación de Medicamentos , Estimación de Kaplan-Meier , Longevidad/efectos de los fármacos , Masculino , Oxígeno/sangre , Conejos , Proteínas Recombinantes/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...